Breast Cancer
This new series of case-based microlearning courses are designed to help pathologists and laboratory professionals increase their knowledge, skills, and competence in applying practice-changing updates regarding HER2-low and HER2-ultralow advanced breast cancer.
This is the first of three activities and focuses on HER2 classification, tracking, and reporting considerations for HER2 IHC testing and interpretations in HER2-low breast cancers.
In the second portion of this three-part activity we focus on the emerging science of HER2-low and HER2-ultralow then go into current treatment for HER2-low and HER2-ultralow patients.
In this final part of the three activities, the focus is on reproducibility of testing and clinical significance of HER2-low and HER2-ultralow.
This microlearning series is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
The ASCP designates this online microlearning activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.